SABCS 2022 | A post hoc analysis of adjuvant radiation therapy in the KEYNOTE-522 study

Heather McArthur, MD, MPH, UT Southwestern Medical Center, Dallas, TX, discusses a post hoc analysis of the Phase III KEYNOTE-522 (NCT03036488) trial which had shown statistically significant and clinically meaningful improvement in pathological complete response (pCR) and event-free survival (EFS) rates in patients with early triple-negative breast cancer (TNBC) with the addition of pembrolizumab to neoadjuvant chemotherapy. Dual primary endpoints are pCR, defined as ypT0/Tis ypN0, and EFS. EFS and adverse events that occurred during the adjuvant phase were examined in patient subgroups defined by receipt of adjuvant radiotherapy and the pattern of adjuvant radiotherapy and pembrolizumab administration, either concurrent or sequential. In this post hoc analysis, the addition of pembrolizumab to neoadjuvant chemo followed by adjuvant pembrolizumab provided a clinically meaningful EFS benefit, independent of adjuvant RT administration. This interview took place at the San Antonio Breast Cancer Symposium (SABCS) 2022 in San Antonio, TX.

These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.